From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

Table 1 Immune-checkpoint inhibitors antibodies with their targets

CKI	Mechanism of action
Nivolumab	Anti-PD-1
Pembrolizumab	Anti-PD-1
Atezolizumab	Anti-PD-L1
Durvalumab	Anti-PD-L1
Avelumab	Anti-PD-L1
BMS936559	Anti-PD-L1
Pidilizumab	Anti-PD-1

CKI: Checkpoint inhibitors.